RxDoctor Payments DataLook up a doctor →

Riple Hansalia, MD

Clinical Cardiac Electrophysiology · Neptune, NJNPI 1669511721

Payments from drug & device makers

$31,241in general payments, 2019–2025

Across 685 payments — averaging $45.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$21K
  • Novartis$1K
  • Medtronic$1K
  • Abbott$1K
  • Johnson & Johnson$834
  • E.r. Squibb & Sons, L.L.C.$700
  • plus $5K from 38 others

What the payments were for

  • Consulting fees$17,37556%
  • Travel & lodging$1,5405%
  • Food & beverage$12,32639%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,241 in reported general payments places this provider in the 60th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.

See all clinical cardiac electrophysiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$1,200,707
Medicare patients
1,832
Services billed
11,403

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban686$944,106
EntrestoSacubitril/Valsartan193$275,213
XareltoRivaroxaban154$214,010
MultaqDronedarone Hcl94$161,798
FarxigaDapagliflozin Propanediol59$75,758
Repatha SureclickEvolocumab104$72,598
JardianceEmpagliflozin37$46,966
Metoprolol Succinate990$22,976
NexlizetBempedoic Acid/Ezetimibe13$12,974
Dabigatran EtexilateDabigatran Etexilate Mesylate21$9,113
Dofetilide40$8,179
Atorvastatin Calcium542$8,085
Valsartan255$8,001
Mexiletine Hcl58$6,628
Diltiazem 24hr Er (Cd)Diltiazem Hcl98$4,689

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$328$944,106686 claims
NovartisEntresto$1,462$275,213193 claims
Johnson & JohnsonXarelto$834$214,010154 claims
Sanofi-aventis U.S. LLCMultaq$295$161,79894 claims
AstraZenecaFarxiga$335$75,75859 claims
Boehringer IngelheimJardiance$380$46,96637 claims
Esperion Therapeutics, Inc.Nexlizet$91$12,97413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.

Other clinical cardiac electrophysiology in Neptune

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →